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Abstract  
BACKGROUND: 1,3/1,6-β–glucans are recognised as immunomodulators in human and veterinary medicine for 
over 50 years. 
AIM: To assess the effects of pleuran (1,3/1,6-β–glucan from Pleurotus ostreatus) on incidence and duration of 
bacterial exacerbations in patients with COPD. 
METHODS: We performed an observational, non-randomized, open-label study including 32 COPD patients 
(Group D) in whom besides the recommended chronic treatment for the stable disease were administered 
supplement combination containing pleuran 100 mg, vitamin C 60 mg and zinc 5 mg once daily over a three 
month-period (Group 1). Also, an equal number of Group D COPD patients who besides the recommended 
treatment for stable disease received the supplement combination containing vitamin C 60 mg and zinc 5 mg 
once daily, matched to the study subjects of the Group 1 by sex and age served as control (Group 2). 
RESULTS: Over the study period 57 exacerbations (24 in the Group 1 and 33 in the Group 2) were documented. 
A mean number of exacerbations over the study period was significantly lower in the Group1 (0.7 ± 0.4) as 
compared to their mean number in the Group 2 (1.0 ± 0.6) (P = 0.0218). Furthermore, a mean duration of 
exacerbations expressed in days needed for cure or clinical improvement (i.e. complete resolution of symptoms or 
return of the symptoms to their baseline severity) in the Group 1 (6.7 ± 0.8 days) was significantly shorter than the 
mean duration of exacerbations in the Group 2 (7.4 ± 1.3 days) (P = 0.0118). There was not reported any adverse 
effect during the study period by study subjects from both examined groups. 
CONCLUSION: Our findings indicated that pleuran might impact the incidence and duration of bacterial 
exacerbations in patients with COPD. There is a need for further studies for more precise determination of the 
influence of pleuran on the course of COPD. 
 
 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) represents one of the principal demands of 
the public health at global level due to high morbidity, 
early mortality, high date rates and significant costs to 
health systems. The projection of the Global Burden 
of Disease Study indicates that COPD in 2020 will be 
the third leading cause of death worldwide (from sixth 
in 1990) and fifth leading cause of years lost 
(disability-adjusted life years - DALYs) through early 
mortality or handicap (12th in 1990) [1]. In addition, 
exacerbations of COPD, defined as acute events 
characterized by worsening of the patient’s respiratory 
symptoms that is beyond normal day-to-day variations 
leading to a change in medications, have substantial 
impact in the course of the disease because they 
negatively affect a patient’s quality of life, accelerate 
the rate of decline of lung function and are associated 
with significant mortality, particularly in those requiring 
hospitalization. The most common cause of COPD 
exacerbations is believed to be bacterial respiratory 
infections [2, 3]. 
β–glucans comprise a diverse group of 
polysaccharides in which glucose molecules are 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  894                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
linked by β-linkages. β-1,3/1,6-glucans are branched 
chains of glucose molecules connected by β-1,3-
glycosidic bonds in which the branching points are β-
1,6 linkages. Some β-1,3/1,6-glucans are bioactive 
interacting with receptors on immune cells eliciting 
specific biological responses. The ability of β-1,3/1,6-
glucans to activate innate immune cells depends on 
its branched structure, i.e. the chain length and the 
frequency of side chains are essential for 
immunomodulating properties of these β–glucans. 
Also, results of several studies indicated that insoluble 
β–glucans (i.e. non-absorbable and non-digestible) 
possessed higher immunomodulating activity than 
soluble ones [4-6].  
β–glucans can be extracted from the cell walls 
of yeast, oat, barley, seaweeds, algae and bacteria, 
but the foremost source of medical glycans turns out 
to be fungal cell walls [7]. Pleuran is an insoluble 
1,3/1,6-β–glucan from mushroom Pleurotus ostreatus. 
Some experimental studies on an animal model, as 
well as some experimental and clinical studies in 
humans,  indicated immunomodulatory properties of 
pleuran that are based on its effects on immune cells 
of the Peyer’s patches in the gut. After oral 
administration, pleuran comes in contact with immune 
cells of the Peyer’s patches which expressed several 
receptors (e.g. Dectin-1, complement receptor-3, 
scavenger receptors, etc.) capable of recognising β–
glucans in their various forms. Upon pleuran’s binding 
to these receptors, a cascade of intracellular signaling 
that stimulates innate and subsequently adaptive 
immune responses is initiated, mainly through release 
of pro-inflammatory cytokines (complement 
components, interleukin-1α/β, interleukin-6, 
interleukin-8, interleukin-12, tumor necrosis factor-, 
eicosanoids, etc.) which improves the resistance to 
invading pathogens [8-11].              
The aim of the present study was to assess 
the effects of pleuran on incidence and duration of 
bacterial exacerbations in patients with COPD.           
 
 
Methods 
 
Study design and setting 
An observational, non-randomized, open 
study (a real life-study) was realized as a comparison 
of frequency and duration of bacterial exacerbations 
between a group D COPD patients who received the 
supplement combination containing pleuran 100 mg, 
vitamin C 60 mg and zinc 5 mg over a three month-
period besides the chronic pharmacological treatment 
for stable disease recommended by actual GOLD and 
a group D COPD patients treated over a three month-
period with the recommended chronic treatment for 
stable disease and the supplement combination 
containing vitamin C 60 mg and zinc 5 mg. It was 
performed in a period December 2016-April 2017 at 
the Institute for Occupational Health of Republic of 
Macedonia, Skopje.  
 
Study subjects 
The study population included 64 COPD 
patients, classified into group D according to the 
combined assessment of the disease, divided into two 
groups. The first group included 32 patients (18 males 
and 14 females, aged 48 to 71 years) who took the 
supplement combination containing pleuran 100 mg, 
vitamin C 60 mg and zinc 5 mg once daily in three 
months besides the recommended pharmacological 
treatment for the stable disease. The second group 
included an equal number of COPD patients (18 
males and 14 females, aged 47 to 73 years) who 
received the supplement combination containing 
vitamin C 60 mg and zinc 5 mg once daily besides the 
recommended treatment for the stable disease, 
matched to the first group by sex, age and smoking 
status.         
Patients with a history of asthma, lung cancer, 
or another significant respiratory disease, as well as 
those unable to complete diary cards,  were excluded 
from the study. All study subjects were recruited in the 
stable phase of the disease, i.e. without any evidence 
of exacerbation for at least three weeks. 
All study subjects were informed about the 
study, and their written consent was obtained. 
Daily stable respiratory symptoms (baseline 
symptoms), medication use and history of 
exacerbations were noted in all subjects before 
entering the study. All study subjects underwent 
baseline and post-bronchodilator spirometry according 
to the actual recommendations of European 
Respiratory Society (ERS) and American Thoracic 
Society (ATS) [3, 12].    
The Body Mass Index (BMI) as a measure of 
body fat based on height and weight that applies to 
adult population was determined in all study subjects 
by computed calculation using BMI calculator [13].    
Classification of smoking status was done by 
the World Health Organization (WHO) 
recommendations [14]. Passive smoking or exposure 
to environmental tobacco smoke was defined as 
exposure to tobacco combustion products from 
smoking by others (at home, workplace, etc.), i.e. as a 
presence of at least one smoker in the household and 
the workplace [15, 16].     
 
Diagnosis and assessment of COPD 
According to the actual Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 
recommendations, COPD was considered by finding 
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of a post-bronchodilator ratio between forced 
expiratory volume in one second and forced vital 
capacity (FEV1/FVC ratio) less than 0.70 in 
symptomatic subjects (dyspnea, chronic cough or 
sputum production) with a history of exposure to risk 
factors for the diseases (noxious particles and gases).  
Subjects with diagnosed COPD were 
classified according to the combined COPD 
assessment which included assessment of symptoms, 
the degree of airflow limitation and risk of 
exacerbations. COPD patients classified as a Group D 
were characterized by frequent symptoms (overall 
score of the COPD Assessment Test [CAT] equal or 
higher than 10), severe or very severe airflow 
limitation (FEV1 value ranging from 30 to 50% of its 
predicted value or less than 30% of its predicted 
value) and high risk of exacerbation (two or more 
exacerbations per year or one or more exacerbations 
requiring hospitalization per year) [2, 3].  
 
Diagnosis and treatment of COPD 
exacerbation 
According to the actual GOLD 
recommendations, COPD exacerbations were 
considered as acute events characterised by a 
worsening of the patient’s respiratory symptoms that 
is beyond normal day-to-day variations and led to a 
change in medication. The diagnosis of exacerbation 
was defined by the patient’s symptoms, using the 
criteria described by Anthonisen et al. [17]. Probable 
bacterial aetiology was established when the 
exacerbation was Anthonisen type I (presence of 
three cardinal symptoms: increased dyspnea, sputum 
volume and purulence) or type II (presence of two 
cardinal symptoms) if increased purulence of sputum 
was one of the two symptoms. 
The treatment of exacerbations with antibiotic 
was started empirically following the actual GOLD 
recommendations. In the cases with positive result of 
microbiological evaluation of sputum, the treatment 
was continued following the finding of the sensitivity of 
bacterias to a certain antibiotic. Oral corticosteroids 
were given as needed (a dose of 40 mg oral 
prednisone per day for five days). The course of 
exacerbation was evaluated as a function of the 
resolution of symptoms, and the treatment was 
considered to be successful if a cure or clinical 
improvement was achieved. The cure was defined as 
complete resolution of the cardinal symptoms, 
whereas the clinical improvement was defined as the 
return of the symptoms to their baseline severity [2, 3, 
17]. 
 
Data collection (Daily diary card) 
All study subjects maintained daily diary cards 
on which they noted any appearance of an increase in 
the intensity of major symptoms (dyspnea, sputum 
amount and sputum purulence) or minor symptoms 
(nasal discharge/congestion, sore throat, wheezing, 
cough, etc.) over their chronic (stable) symptoms. A 
member of the study team saw study subjects within 
48 hours of the detection of deterioration in symptoms 
and diagnosis was confirmed of each case. 
Exacerbation and its resolution were defined as it is 
mentioned above. Exacerbation number and their 
duration were calculated for each study subjects 
based on data from diary cards for a three month-
period of follow-up.     
 
Statistical analysis 
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 11.0 for Windows. Continuous variables were 
expressed as mean values with standard deviation 
(SD), and the nominal variables as numbers and 
percentages. Analyses of the data included testing the 
differences in prevalence and comparison of the 
means by chi-square test (or Fisher’s exact test where 
appropriate) and independent-samples T-test. A P-
value less than 0.05 were considered as statistically 
significant. 
 
 
Results 
 
Demographic characteristics of the study 
subjects are shown in Table 1. 
Table 1: Demographics of the study subjects 
Variable Group1 
(n = 32) 
Group 2 
(n = 32) 
M/F ratio 
Mean age (years) 
Mean BMI (kg/m
2
)  
 
1.4 
58.7  6.4 
25.9  3.3 
1.4 
59.4  7.2 
26.6  2.8 
Mean duration of COPD (years) 
Mean values  
of spirometric parameters (% pred.) 
FVC 
FEV1 
FEV1/FVC ratio 
 
Treatment of stable COPD 
LA 2-agonist + ICS 
LA anticholinergic 
Oral theophylline  
11.7  4.2 
 
67.6  7.1 
42.3  4.4 
0.63  0.03 
 
 
25 (78.1%) 
22 (68.8%) 
6 (18.7%) 
10.9  5.1 
 
68.7  6.8 
43.4  4.1 
0.64  0.02 
 
 
26 (81.2%) 
23 (71.8%) 
5 (15.6%) 
 
Number of exacerbations  
in the previous year 
 
Smoking status 
Active smokers 
Ex-smokers 
Never smokers 
Exposed to ETS 
 
Comorbidities 
Arterial hypertension 
Osteo-muscular disorders 
Ischaemic heart disease 
Diabetes mellitus type 2 
 
 
 
2.6  0.3 
 
 
11 (34.3%) 
17 (53.1%) 
4 (12.5%) 
15 (46.8%) 
 
 
9 (28.1%) 
5 (15.6%) 
4 (12.5%) 
3 (9.4%) 
 
 
2.7  0.4 
 
 
9 (28.1%) 
19 (59.4%) 
4 (12.5%) 
18 (56.2%) 
 
 
8 (25.0%) 
7 (21.8%) 
5 (15.6%) 
4 (12.5%) 
 
 
Numerical data are expressed as a mean 
value with standard deviation; frequencies as number 
and percentage of study subjects with a certain 
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variable. 
COPD: chronic obstructive pulmonary 
disease; M: male; F: female; BMI: body mass index; 
kg: kilogram; m: meter; % pred.: % of the predicted 
value; FVC: forced vital capacity; FEV1: forced 
expiratory volume in one second; LA: long-acting; 
ICS: inhaled corticosteroid; ETS: environmental 
tobacco smoke. 
Over the study period, 57 exacerbations were 
documented (24 in the Group 1 and 33 in the Group 
2) of which 12 required hospital treatment (five in the 
Group 1 [20.8%] and seven in the Group 2 [21.2%]). 
43 of the 57 (75.4%) were treated only with oral 
antibiotics (19/24 [79.2%] in the Group1 and 24/33 
[72.7%] in the Group 2) and 14 (24.6%) were treated 
with antibiotics and oral prednisolone (5/24 [20.8%] in 
the Group 1 and 9/33 [27.3%] in the Group 2). 
A mean number of exacerbations over the 
study period was significantly lower in the Group1 (0.7 
± 0.4) as compared to their mean number in the 
Group 2 (1.0 ± 0.6) (P = 0.0218) (Figure 1). 
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Figure 1: Mean number of exacerbations in the examined groups 
A mean duration of exacerbations expressed 
in days needed for cure or clinical improvement (i.e. 
complete resolution of symptoms or return of the 
symptoms to their baseline severity) in the Group 1 
(6.7 ± 0.8 days) was significantly shorter than the 
mean duration of exacerbations in the Group 2 (7.4 ± 
1.3 days) (P = 0.0118) (Figure 2). 
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Figure 2: Mean duration of the exacerbations in the examined 
groups 
Side effects of the used medicaments over 
the study period were not reported by any study 
subject from both examined groups. 
 
 
Discussion 
 
Pharmacological treatment of stable COPD is 
used to reduce symptoms, reduce frequency and 
severity of exacerbations, and improve health status 
and exercise tolerance. Existing medications for 
stable COPD have not been conclusively shown to 
modify the long-term decline in lung function that is 
the hallmark of the disease [2, 3]. As it is mentioned 
above, COPD is one of the most important public 
health problems in the last decades worldwide, so 
there are many investigations into new and more 
effective therapeutic options. 
In the present study, we assessed the effects 
of pleuran (1,3/1,6-β–glucan from Pleurotus ostreatus) 
on the incidence and duration of exacerbations in 
patients with COPD. To our knowledge, the present 
study was the first one that investigated effects of 
pleuran on prevention of exacerbations in COPD 
patients. Examined groups included COPD patients 
classified into Group D, i.e. the COPD patients 
characterised by frequent symptoms, severe or very 
severe airflow limitation and high risk of exacerbation. 
Study subjects from both examined groups had similar 
demographic characteristics. Although tobacco smoke 
is recognised as the most important risk factor of 
COPD, in both groups, we found a large proportion of 
active and passive smokers which did not differ 
significantly from their prevalence in the general 
population in R. Macedonia documented in our 
previous studies [18, 19]. These findings suggested 
insufficient anti-smoking activities of healthcare 
workers among COPD patients besides smoking 
cessation is recommended as the first therapeutic 
option in the non-pharmacological treatment of the 
disease [2, 3]. 
The immunomodulatory properties of fungal β 
-glucans were studied and described almost 50 years 
ago. Shortly afterwards, in experimental animals were 
described their effects against a tumour. Finally, there 
is evidence that β-glucans may modulate other 
conditions (cholesterol level, glucose tolerance, etc.). 
[20-22]. As it is mentioned above, many studies have 
reported the ability of pleuran to activate innate 
immunity with effects also on adaptive immunity, 
inducing humoral and cell-mediated immune 
responses. Pleuran was found to increase the 
antimicrobial activity of mononuclear cells and 
neutrophils and enhance the functional activity of 
macrophages.  
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Findings of our studies showed significantly 
lower incidence, as well as the significantly shorter 
duration of exacerbations in COPD patients treated 
with pleuran besides regular treatment of stable 
disease as opposite to their incidence and duration in 
COPD patients treated only with the regular treatment 
of stable disease. Similar findings were reported by 
several studies which investigated effects of pleuran 
on incidence, duration and severity of respiratory 
infections in both children and adults. Results from the 
double-blinded, placebo-controlled, randomized, 
multicentric study carried out by Jesenak et al. 
including 175 children (mean age 5.65 ± 2.39 years) 
treated with pleuran over the 12 month-period 
indicated significant reduction of the frequency of 
recurrent respiratory tract infections in children treated 
with pleuran as compared to children who did not use 
it [23]. Similar findings were obtained from the study 
carried out by Pico Sirvent et al. including 166 children 
aged 1 to 10 years from 20 pediatric departments in 
Northeast Spain [24].  
Results from the double-blind, placebo-
controlled, randomized study carried out by 
Bergendiova et al. including 50 athletes treated with 
pleuran over the 3 month-period indicated significant 
reduction of the frequency of upper respiratory tract 
infections as compared to their frequency in athletes 
treated with placebo. Furthermore, the authors found 
significantly higher number of circulating natural killers 
cells in pleuran group as compared to their number in 
the placebo group [25]. In addition, in the study which 
investigated effects of pleuran on changes in the 
peripheral blood cells after acute, exhausting physical 
load in 22 elite athletes Bobovcak et al. found no 
statistically significant reduction in natural killers cell 
activity in the group treated with pleuran as opposite 
to the finding of significant reduction in natural killer 
cell activity after intensive exercise in the placebo 
group [26]. 
As it is mentioned above, pleuran as an 
insoluble substance is non-absorbable and non-
digestible, so systemic adverse effects could not be 
expected. As in the case of the present study, local 
(i.e. gastrointestinal) adverse effects were not 
registered in all cited studies.                     
The present study must be interpreted within 
the context of its limitations. The results should be 
viewed with caution, since the study was neither 
blinded nor randomized and, therefore, can be a 
subject to possible selection bias. On the other hand, 
the study design may be its strength, as it is 
documented by other real life-studies. Also, the small 
number of the subjects in the examined groups could 
have certain implications on the data obtained and its 
interpretation. The short follow-up period could also 
have certain implications on the data obtained and its 
interpretation. Furthermore, in the study groups were 
included only Group D COPD patients that that could 
impact results of the study. 
In conclusion, in an observational, non-
randomized, open-label study including a Group D 
COPD patients who received the supplement 
combination containing pleuran 100 mg, vitamin C 60 
mg and zinc 5 mg besides recommended chronic 
pharmacological treatment for stable disease over 
three months we found significantly lower incidence 
and significantly shorter duration of bacterial 
exacerbations as compared to their incidence and 
duration in a Group D COPD patients who took the 
supplement combination containing vitamin C 60 mg 
and zinc 5 mg besides the recommended treatment 
for stable disease in the same period. Our findings 
suggested that the use of pleuran may be beneficial in 
the prevention of exacerbations in the patients with 
COPD. Further investigations, as well as comparisons 
to the other therapeutic modalities, are needed for 
assessment of the preventive effects of pleuran 
regarding the COPD exacerbations.   
 
Ethical Approval 
The Ethical Committee of the Institute of 
Occupational Health of R. Macedonia, Skopje – WHO 
Collaborating Center and GA2LEN Collaborating 
Center approved for performing the study and 
publishing the results obtained (03-48/23.01.2017). 
 
Authors Participations 
JM participated in the study design, data 
collection, managing the analyses of the study, and 
writing all versions of the manuscript. JKB and TP 
participated in the study design and managing the 
analyses of the study. KV performed the statistical 
analysis and participated in the managing the 
analyses of the study. SS and DM participated in the 
data collection and the managing the analyses of the 
study. All authors read and approved the final 
manuscript.  
 
 
References 
1. Mathers CD, Loncar D. Projections of global mortality and 
burden of disease from 2002 to 2030. PloS Med. 2006; 3: e442. 
https://doi.org/10.1371/journal.pmed.0030442 PMid:17132052 
PMCid:PMC1664601 
2. Global Strategy for the Diagnosis, Management, and Prevention 
of Chronic Obstructive Pulmonary Disease: 2014 Update. Available 
at: http://www.goldcopd.org/ (Accessed 14.04.2017). 
 
3. Global Initiative for Chronic Obstructive Pulmonary Disease. A 
pocket guide to COPD diagnosis, management and prevention: 
Updated 2015. Available at: http://www.goldcopd.org/ (Accessed 
14.04.2017). 
 
4. Bohn JA, BeMiller JN. (1-3)-beta-D-glucans as biological 
response modifiers: a review of structure-function relationships. 
Carbohydr Polymers. 1995; 28: 3-14. https://doi.org/10.1016/0144-
8617(95)00076-3 
 
5. Raa J. Immune modulation by non-digestible and non-
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  898                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
apsorbable beta-1,3/1,6-glucan. Microbial Ecology in Health & 
Disease. 2015; 26: 27824. https://doi.org/10.3402/mehd.v26.27824 
PMid:26031679 PMCid:PMC4451094 
6. Vannucci L, Krizan J, Sima P, et al. Immunomodulatory 
properties and antitumor activities of glucans (Review). 
International Journal of Oncology. 2013; 43: 357-364. 
https://doi.org/10.3892/ijo.2013.1974 PMid:23739801 
PMCid:PMC3775562 
 
7. Yap AT, Ng ML. An important method for the isolation of lentina 
from edible and medicinal shitake mushroom, Lentinus edodes 
(Berk.) Sing. (Agaricomycetideae). In J Med Mushr. 2001; 3: 6-19. 
 
8. Brown GD, Gordon S. Immune recognition. A new receptor for 
beta-glucans. Nature. 2001; 413: 36-37. 
https://doi.org/10.1038/35092620 PMid:11544516  
 
9. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition 
by the innate immune system. Immunol Rev. 2009; 230 (1): 38-50. 
https://doi.org/10.1111/j.1600-065X.2009.00793.x PMid:19594628  
 
10. Batbayar S, Lee DH, Kim HW. Immunomodulation of fungal -
glucan in host defense signaling by dectin-1. Biomol Ther. 2012; 20 
(5): 433-445. https://doi.org/10.4062/biomolther.2012.20.5.433 
PMid:24009832 PMCid:PMC3762275 
 
11. Volman JJ, Ramakers JD, Plat J. Dietary modulation of 
immune function by beta-glucans. Physiol Behav. 2008; 94: 276-
284. https://doi.org/10.1016/j.physbeh.2007.11.045 
PMid:18222501  
 
12. Spirometry Guide: 2010 Update. Available at: 
http://www.goldcopd.org/uploads/users/files/GOLD_Spirometry_20
10. (Accessed: 16.04.2017). 
 
13. Calculate your Body Mass Index. Available at: 
https://www.nhlbi.nih.gov (Accessed: 16.04.2017).  
14. World Health Organization. Guidelines for controlling and 
monitoring the tobbaco epidemic. Geneva: WHO, 1998.  
15. U.S. Department of Health and Human Services. The health 
consequences of smoking: chronic obstructive pulmonary disease. 
A report of the Surgeon General. US Department of Health and 
Human Services, Public Health Service, Office of the Assistant for 
Health, Office of Smoking and Health. DHHS Publication No. 84-50 
205, 1984. 
 
16. Janson C, Chinn S, Jarvis D, et al. Effects of passive smoking 
on respiratory symptoms, bronchial responsiveness, lung function, 
and total serum IgE in the European Community Respiratory 
Health Survey: a cross-sectional study. Lancet. 2001; 358: 2103-
2109. https://doi.org/10.1016/S0140-6736(01)07214-2 
 
17. Anthonisen NR, Menfreda J, Warren CP, et al. Antibiotic 
therapy in exacerbations of chronic obstructive pulmonary disease. 
Ann Intern Med. 1987; 106 (2): 196-204. 
https://doi.org/10.7326/0003-4819-106-2-196 PMid:3492164  
 
18. Minov J, Karadzinska-Bislimovska J, Nelovska Z, Vasilevska K, 
Risteska-Kuc S, Stoleski S, Mijakoski D. Smoking among 
Macedonian workers five years after anti-smoking campaign. Arh 
Hig Rada Toksikol. 2012; 63: 207-213. 
https://doi.org/10.2478/10004-1254-63-2012-2150 PMid:22728803  
 
19. Minov J. Smoking among Macedonian Workers. Saarbrücken: 
LAP LAMBERT Academic Publishing, 2013.  
20. Cassone A, Bistoni F, Cenci E, et al. Immunopotentiation of 
anticancer therapy by Candida albicans, other yeasts and insoluble 
glucan in an experimental lymphoma model. Sabouraudia. 1982; 
20: 115-125. https://doi.org/10.1080/00362178285380191 
PMid:7051368  
 
21. Zhang Y, Xia L, Pang W, et al. A novel soluble β-1,3-d-glucan 
Salecan reduces adiposity and improve glucose tolerance in high-
fat diet-fed mice. Br J Nutr. 2012; 13: 1-9. 
 
22. Haggard L, Andersson M, Punga AR. -glucans reduce LDL 
cholesterol in patients with myastenia gravis. Eur J Clin Nutr. 2013; 
67: 226-227. https://doi.org/10.1038/ejcn.2012.191 PMid:23187951  
 
23. Jesenak M, Majtan J, Rennerova Z, et al. Immunomodulatory 
effect of pleuran (-glucan from Pleurotus ostreatus) in children 
with recurrent respiratory tract infections. Int Immunopharmacol. 
2013; 15 (2): 395-399. https://doi.org/10.1016/j.intimp.2012.11.020 
PMid:23261366  
 
24. Pico Sirvent L, Sapena Grau J, Morera Ingles M, Rivero Urgell 
M. Effect of supplementation with β–glucan from Pleurotus 
ostreatus in children with recurrent respiratory infections. Ann Nurr 
Metab. 2013; 63 (1): 1378. 
 
25. Bergendiova K, Tibenska E, Majtan J. Pleuran (-glucan from 
Pleurotus ostreatus) supplementation, cellular immune response 
and respiratory tract infections in athletes. Eur J Appl Physiol. 
2011; 111 (9): 2033-2040. https://doi.org/10.1007/s00421-011-
1837-z PMid:21249381  
 
26. Bobovcak M, Kuniakova R, Gabriz J, Majtan J. Effect of 
Pleuran ((-glucan from Pleurotus ostreatus) supplementation on 
cellular immune response after intensive exercise in elite athletes. 
Appl Physiol Nutr Metab. 2010; 35 (6): 755-762. 
https://doi.org/10.1139/H10-070 PMid:21164546  
 
 
